What Priovant Therapeutics does

Priovant Therapeutics is a clinical-stage biotechnology company developing brepocitinib, a dual TYK2/JAK1 inhibitor, as an oral targeted therapy for severe autoimmune diseases with significant unmet medical need. The company was established as a subsidiary of Roivant Sciences and licensed brepocitinib from Pfizer in 2021, with Pfizer retaining a 25% ownership stake in Priovant as part of that transaction. Brepocitinib is being advanced across four late-stage indications: dermatomyositis (NDA accepted with FDA Priority Review and a PDUFA target action date in Q3 2026), cutaneous sarcoidosis (FDA Breakthrough Therapy Designation; Phase 3 planned following positive Phase 2 BEACON data), non-infectious uveitis (Phase 3 topline data expected in the second half of 2026), and lichen planopilaris (Phase 2b/3 enrollment initiated March 2026). The Phase 3 VALOR trial in dermatomyositis enrolled 241 patients across 90 global sites and met all nine key secondary endpoints with a 15.3-point greater Total Improvement Score improvement versus placebo at Week 52 (P<0.001). Each of the primary indications—dermatomyositis, cutaneous sarcoidosis, and lichen planopilaris—currently lacks any FDA-approved targeted therapy, positioning brepocitinib as a potential first-in-class oral treatment.

The company operates a specialty pharmaceutical commercial model targeting rare autoimmune disease patient populations via specialty pharmacy distribution and direct physician outreach to rheumatologists and dermatologists. A US commercial launch for brepocitinib in dermatomyositis is planned for the end of September 2026 contingent on FDA approval, supported by survey evidence of strong prescribing intent among 103 US rheumatologists and peer-reviewed publication in the New England Journal of Medicine. Priovant has 11–50 employees, is headquartered in New York, and is majority-owned by Roivant Sciences (NASDAQ: ROIV) with Pfizer holding a 25% minority stake. As a pre-commercial clinical-stage company, Priovant does not currently generate product revenue, has not publicly disclosed launch pricing, and is funded through its parent company.

Name

Priovant Therapeutics

Legal name

Priovant Therapeutics, Inc.

Website

https://priovanttx.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Priovant Therapeutics is a clinical-stage biotechnology company developing brepocitinib, a dual TYK2/JAK1 inhibitor, as an oral targeted therapy for severe autoimmune diseases including dermatomyositis, cutaneous sarcoidosis, non-infectious uveitis, and lichen planopilaris.

Ownership category

akta.pro rank

Product category

Autoimmune Disease Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industries

Rare Dermatology Disorder Therapies (HLAIAIAM), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Autoimmune disease therapeutics
• Tyrosine kinase inhibitors
• Clinical stage biotechnology
• Inflammatory disease drugs
• Orphan drug development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical product sales: Pre-commercial stage company preparing for launch of brepocitinib following FDA approval. If approved, brepocitinib would be the first targeted therapy for dermatomyositis, representing a significant unmet medical need.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Priovant Therapeutics is a clinical-stage biopharmaceutical company developing brepocitinib, an oral dual TYK2/JAK1 inhibitor, for severe autoimmune diseases with limited treatment options. The company is focused on indications including dermatomyositis, cutaneous sarcoidosis, non-infectious uveitis, and lichen planopilaris, with U.S. FDA approval and commercial launch targeted for 2026.

Product overview

Priovant Therapeutics is a clinical-stage biotechnology company developing targeted therapies for patients with severe autoimmune diseases. The company's lead product is brepocitinib, a dual TYK2/JAK1 inhibitor, which represents the core of its late-stage development pipeline spanning four indications: dermatomyositis (under FDA Priority Review for Q3 2026 approval decision), lichen planopilaris (Phase 2b/3), cutaneous sarcoidosis (Phase 3 planned for 2026), and non-infectious uveitis (Phase 3 topline data expected H2 2026). The company was formed as a Roivant subsidiary with a license from Pfizer (which retains a 25% stake in Priovant).

Differentiator

Problem solved

Functional benefit

Products and services

• Brepocitinib Brepocitinib is an oral small-molecule dual TYK2/JAK1 inhibitor being developed as a targeted therapy for severe autoimmune diseases, including dermatomyositis, cutaneous sarcoidosis, non-infectious uveitis, and lichen planopilaris. It is intended for prescription by specialist physicians (e.g., dermatologists, rheumatologists, ophthalmologists, uveitis specialists) for adult and pediatric patients with limited or no approved treatment alternatives.

Quantifiable outcome

• 15.3-point greater improvement in Total Improvement Score at Week 52 versus placebo (P<0.001)
• +4 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• PfizercoreOEM/ Whitelabel/ Licensing Partner · 1 January 2021Licensed brepocitinib (formerly PF-06700841) from Pfizer in 2021 for development in autoimmune diseases. Pfizer retains a 25% ownership stake in Priovant Therapeutics. The agreement provides Priovant with rights to develop and commercialize brepocitinib across multiple indications.

Scale indicators5 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Arcutis Biotherapeutics: Specialty dermatology-focused biopharma developing and commercializing topical and oral therapies for inflammatory skin diseases. Highly comparable as a similarly-sized, late-stage commercializing dermatology/autoimmune biotech navigating a similar first-launch dynamic.

Broad incumbents

• Bristol Myers Squibb: Markets deucravacitinib (Sotyktu), a selective TYK2 inhibitor approved in psoriasis with label-expansion underway into other autoimmune dermatology indications. Directly competes with brepocitinib's TYK2 inhibition mechanism in autoimmune skin disease.
• AbbVie: Markets upadacitinib (Rinvoq), a JAK1 inhibitor approved across multiple autoimmune indications including rheumatology and dermatology. Represents the dominant JAK franchise competitor Priovant will face in autoimmune disease.
• Pfizer: Original developer and licensor of brepocitinib with a retained 25% stake; also markets abrocitinib (Cibinqo), a JAK1 inhibitor in atopic dermatitis. Comparable as the parent-asset originator and a competing JAK1 player in dermatology.
• Eli Lilly: Markets baricitinib (Olumiant), an oral JAK1/2 inhibitor approved in rheumatoid arthritis and other autoimmune indications, and acquired Dice Therapeutics (TYK2). Comparable as a large JAK-class competitor with overlapping autoimmune development programs.
• Takeda Pharmaceutical: Acquired Nimbus Lakshmi's TYK2 program and has active autoimmune and rare disease franchises. Comparable as a large incumbent with a competing TYK2 asset and broad autoimmune commercial infrastructure.
• Sanofi: Markets dupilumab (Dupixent) across multiple type-2 and other inflammatory indications including dermatology. Comparable as a dominant immunology incumbent whose commercial footprint and physician relationships shape Priovant's launch environment.

Emerging players

• MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing sonelokimab (an IL-17A/F nanobody) in inflammatory skin and joint diseases including hidradenitis suppurativa. Comparable as a similarly-sized late-stage emerging dermatology/autoimmune biotech advancing rare inflammatory indications.
• AnaptysBio: Clinical-stage immunology company developing IL-36 and checkpoint agonist/antagonist antibodies in inflammatory and autoimmune diseases. Comparable as a similarly-sized clinical-stage biotech targeting inflammatory disease pathways with multiple indications.
• Galapagos NV: Biotech focused on JAK1 inhibition (filgotinib) and CAR-T therapies in inflammation and oncology. Comparable as a developer of selective JAK1 inhibitors in autoimmune disease with overlapping mechanism positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Priovant Therapeutics